Medical Advocates
HIV/HCV Coinfection
 
Antiretroviral Drugs
HAART/ART: General Reports 
Direct Acting Antiretrovirals
 Abacavir                    
Atazanavir    
Darunavir          
Didanosine
Etravirine
Lopinavir
Maraviroc		 Raltegravir
Ritonavir
Tenofovir
Tipranavir
Zidovudine
Peginterferons
 
HIV/HCV Main Page Main New/Newsworthy  Home Page
Last Update:  November 10, 2017  
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
HAART/ART General Reports
 

    Journal Papers, Abstracts, and Commentaries
 
 

The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy.
Lee S, Laiman A, French MA, et al
Clin Immunol. 2017 Mar 14
 Abstract

Mechanisms and Consequences of Drug-Drug Interactions.
Greenblatt DJ.
 Clin Pharmacol Drug Dev. 2017 Mar;6(2):118-124. .
 Abstract

Directly acting antivirals (DAAs) for HCV arrive in HIV/HCV co-infected patients: from 'mind the gap' to 'where's the gap?'
 Childs K, Taylor C, Dieterich D, Agarwal K.
AIDS. 2016 Feb 1
 Abstract

FULL-TEXT PDF ARTICLE
Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.
Bagaglio S, Messina E, Hasson H, et al
New Microbiol. 2017 Jan 5;40(1).
Paper

HIV Protease Inhibitors Associated with Increased HCV Viral Load in Coinfected Patients.
Labarga P.
AIDS Rev. 2015 Jul-Sep;17(3):186.
 Abstract

FULL-TEXT ARTICLE
Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART)
Dold L, Ahlenstiel G, Althausen E, et al
PLoS One. 2015 Aug 4;10(8):e0134158.
Paper

Influence of hepatitis C virus coinfection on CD4+ T cells of HIV-infected patients receiving HAART.
 Shmagel KV, Saidakova EV, Korolevskaya LB,  et al
AIDS. 2014 Aug 7.
 Abstract

HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals.
 Bichoupan K, Dieterich DT, Martel-Laferrière V.
Curr HIV/AIDS Rep. 2014 Jul 5.
Abstract

Reversible hepatic decompensation following cessation of antiretroviral therapy in a patient with HIV and hepatitis C co-infection.
Croucher AP, Main J.
Int J STD AIDS. 2014 Jan 29.
 Abstract

Impact of HCV treatment and depressive symptoms on adherence to HAART among coinfected HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort.
 Roux P, Lions C, Cohen J, Winnock M,  et al
Antivir Ther. 2013 Oct 28. .
 Abstract

Hepatitis C Direct-acting Antiviral Agents: Changing the Paradigm of Hepatitis C Treatment in HIV-infected Patients.
 Martel-Laferrière V, Bichoupan K, Dieterich DT
 J Clin Gastroenterol. 2013 Oct 28.
Abstract

Antiretroviral and Anti-Hepatitis C Virus Direct-Acting Antiviral-Related Hepatotoxicity.
Han H, Agarwal R, Martel-Laferriere V, Dieterich DT.
Clin Liver Dis. 2013 Nov;17(4):657-670.
 Abstract

Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment.
Hua L, Andersen JW, Daar ES,, et al
AIDS. 2013 Aug 6.
 Abstract

Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Vispo E, Fernández-Montero JV,  et al
AIDS. 2013 Apr 24;27(7):1187-8
 Abstract

FULL-TEXT PDF ARTICLE
Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors
Cassol  E , Misra V, Holman  A, et al
BMC Infectious Diseases 2013, 13:203
 Paper

Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.
Grint D, Peters L, Reekie J,et al
HIV Med. 2013 Mar 27.
 Abstract

Long-term safety and tolerability of nevirapine and efavirenz-containing regimens in HIV/HCV-coinfected patients.
 Mauelshagen A, Horst H, Stellbrink H, Hoffmann C.
J Int AIDS Soc. 2012 Nov 11;15(6):18416.
Abstract

Impact of Hepatitis C Virus on HIV Response to Antiretroviral Therapy in Nigeria.
Agbaji O, Thio CL, Meloni S,  et al
J Acquir Immune Defic Syndr. 2012 Nov 28.
 Abstract

HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.
Ingiliz P, Rockstroh JK
 Liver Int. 2012 Apr 17
 Abstract

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog
or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients.
Macías J, Neukam K, Mallolas J,  et al
HIV Clin Trials. 2012 Mar-Apr;13(2):61-9.
Abstract

Risk of elevated TC/HDL-C ratio after antiretroviral therapy in HIV/HCV patients.
Kakinami L, Block RC, Adams MJ,  et al
AIDS Res Hum Retroviruses. 2012 Mar.
 Abstract

HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
 Jones M, Núñez M.
Curr Opin HIV AIDS. 2011 Nov;6(6):546-52.
 Abstract

Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV
co-infected patients.
Plaza Z, Soriano V, Del Mar Gonzalez M, et al
J Antimicrob Chemother. 2011 Sep 27
 Abstract

Natural polymorphisms associated with resistance to new antivirals against HCV in newly
diagnosed HIV-HCV-coinfected patients.
Treviño A, de Mendoza C, Parra P, et al
Antivir Ther. 2011;16(3):413-6..
Abstract

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in
HIV/HCV-coinfected patients.
Trimoulet P, Belzunce C, Faure M,  et al
HIV Med. 2011 Mar 16.
Abstract

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic
hepatitis C.
Macías J, Neukam K, Portilla J, Iribarren JA,  et al
J Antimicrob Chemother. 2011 Mar 10
 Abstract

Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression
in HIV-HCV coinfection before and after antiretroviral therapy. 
Potter M, Odueyungbo A, Yang H, et al 
AIDS. 2010 May
 Abstract

Impact of Hepatitis C Virus Coinfection on HAART in HIV-Infected Individuals:
Multicentric Observation Cohort.
 Fuping G, Wei L, Yang H,  et al
J Acquir Immune Defic Syndr. 2010 Apr 26.
 Abstract

Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients.
 Winters MA, Chary A, Eison R, et al
J Med Virol. 2010 Mar 24;82(5):791-798.
Abstract

Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
 Iorio A, Marchesini E, Awad T, Gluud LL.
 Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004888.
 Abstract
 
Direct Acting Antiretrovirals
 

     Journal Papers, Abstracts, and Commentaries

  Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
Tempestilli M, Fabbri G, Mastrorosa I, et al
 J Antimicrob Chemother. 2017 Nov 2.
 Abstract

Direct-acting antivirals for HIV/HCV co-infected individuals: as good as it gets?
Bruno G, Saracino A.
 Curr HIV Res. 2017 Nov
Abstract

High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.
Macías J, Monge P, Mancebo M, et al
 HIV Med. 2016 Nov 24.
Abstract

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
Casado JL, Mena A, Bañón S, et al
HIV Med. 2015 Jun 30
 Abstract
Abacavir
     
     Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
 Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
 Hepatitis C- working group for COHERE in Eurocoord, Smit C, Arends J, Peters L, et al
 BMC Infect Dis. 2015 Nov 4;15:498
 Paper

Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.
 Laufer N, Laguno M, Perez I, et al  
Antivir Ther. 2008;13(7):953-7
 Abstract
Atazanavir
     
     Journal Papers, Abstracts, and Commentaries
 
 
Severe hyperbilirubinemia in an HIV-HCV coinfected patient starting the 3D regimen that resolved after TDM-guided atazanavir dose reduction.
Cattaneo D, Riva A, Clementi E, et al
Ther Drug Monit. 2016 Feb 25.
 Abstract

Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
Rivero-Juarez A, Lopez-Cortes LF, Girón-Gonzalez JA, et al
 Lancet Infect Dis. 2014 Jan;14(1):13-4.
 Abstract

The use of atazanavir in hiv infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or meld score.
Rodriguez JM, Hermida JM, Casado JL, et al
AIDS. 2011 Mar 17.
 Abstract

Short-Term Effect of Ritonavir-Boosted Atazanavir in Hepatitis B and/or C Co-infected, Treatment-Experienced HIV Patients.
 Pérez-Elías MJ, Gatell JM, Flores J, et al
HIV Clin Trials. 2009 Jul-Aug;10(4):269-75|
 Abstract

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.
 Rodríguez-Nóvoa S, Morello   
 AIDS. 2008 Nov 30;22(18):2535-7
 Abstract

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
 Pineda JA, Santos J, Rivero A, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract
 
Darunavir
     
     Journal Papers, Abstracts, and Commentaries
 
  Darunavir and Ritonavir Total and Unbound Plasmatic Concentrations in HIV-HCV Co-Infected Patients with Hepatic Cirrhosis Compared to HIV Mono-Infected Patients.
 Curran A, Martí R, López RM, Pérez M, et al
Antimicrob Agents Chemother. 2015 Aug 17.|
 Abstract

Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Calza L, Danese I, Colangeli V, et al
Infect Dis (Lond). 2015 Apr 15:1-12.
 Abstract

Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients.
 Morsica G, Bianchi G, Bagaglio S,  et al
New Microbiol. 2011 Jul;34(3):317-21
 Abstract

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3.
Rachlis A, Clotet B, Baxter J, et al
HIV Clin Trials. 2007 Jul-Aug;8(4):213-20.
 Abstract
 
    Conference Reports, Abstracts, and Posters
 
  HCV co-infection does not compromised darunavir monotherapy efficacy in HIV-infected patients, though induce higher immune activation profiles
O.-J. Ben-Marzouk Hidalgo, A. Torres-Cornejo, et al
 (XIX International AIDS Conference)
 Abstract
Didanosine
 

     Journal Papers, Abstracts, and Commentaries

 
Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients.
Vispo E, Maida I, Barreiro P, et al 
HIV Clin Trials. 2008 Jan 1;9(6):440-444
 Abstract
 
Nucleoside analogues and mitochondrial toxicity.
 Fleischer R, Boxwell D, Sherman KE. 
Clin Infect Dis. 2004 Apr 15;38(8):e79-80
 Abstract

Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activityagainst HIV-1 and hepatitis C virus.
 Klein MB, Campeol N, Lalonde RG, et al.  
 AIDS 2003 May 2;17(7):1001-1008
 Abstract

  
Efavirenz
     
     Journal Papers, Abstracts, and Commentaries
 
 
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Calza L, Danese I, Colangeli V, et al
Infect Dis (Lond). 2015 Apr 15:1-12.
 Abstract

Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
 Pineda JA, Neukam K, Mallolas J,  et al
J Infect. 2011 Nov 25.
Abstract

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
 Neukam K, Mira JA, Ruiz-Morales J, et al
J Antimicrob Chemother. 2011 Sep 7.
Abstract
Etravirine
 

     Journal Papers, Abstracts, and Commentaries

  Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
Casado JL, Mena A, Bañón S, et al
HIV Med. 2015 Jun 30
 Abstract
Fosamprenavir
     
     Journal Papers, Abstracts, and Commentaries
 
 
Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1-Infected Patients With or Without Hepatitis B or C Coinfection.
 Ha B, Wine B, Rodriguez-Alcantra F, Shaefer M.
HIV Clin Trials. 2012 May-Jun;13(3):171-
 Abstract
Lopinavir
 

     Journal Papers, Abstracts, and Commentaries

 
Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment.
Khaykin P, Kotzerke P, Stephan C, et al
Ther Drug Monit. 2014 Apr;36(2):192-20
 Abstract
FULL-TEXT PDF ARTICLE
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study).
Hasson H, Galli L, Gallotta G, Neri V,  et al 
New Microbiol. 2012 Oct;35(4):469-74
Paper

A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.
 Cooper C, la Porte C, Tossonian H,  et al
HIV Clin Trials. 2012 Jul-Aug;13(4):179-88.
 Abstract

Safety and Pharmacokinetics of Lopinavir in HIV/HCV Coinfected Patients with Advanced Liver Disease.
Casado JL, Del Palacio M, Moya J, et al
HIV Clin Trials. 2011 Sep-Oct;12(5):235-43.
 Abstract

Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
Calza L, Mosca L, Pocaterra D, et al
Eur J Clin Pharmacol. 2010 Sep 28
 Abstract
Maraviroc
 
     Journal Papers, Abstracts, and Commentaries
 
  Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
 Crespo M, Navarro J, Moreno S, et al
Enferm Infecc Microbiol Clin. 2016 Apr 6.
 Abstract

Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
Rockstroh JK, Soriano V, Plonski F, et al 
HIV Clin Trials. 2015 Apr;16(2):72-80.
 Abstract

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study.
Gagliardini R, Rossetti B, Bianco C,  et al
 J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19818.
 Abstract

Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program.
 Lazzarin A, Than S, Valluri SR, et al
HIV Clin Trials. 2012 Mar-Apr;13(2):83-9
 Abstract


Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
 Macías J, Viloria MM, Rivero A, et al 
Eur J Clin Microbiol Infect Dis. 2012 Jan 19.
 Abstract
Nelfinavir
 

     Journal Papers, Abstracts, and Commentaries

  Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected
patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE, Shire NJ, Cernohous P, et al
Clin Infect Dis. 2005 Oct 15;41(8):1186-95.
 Abstract
Nevirapine
 

   Journal Papers, Abstracts, and Commentaries

Long-term safety and tolerability of nevirapine and efavirenz-containing regimens in HIV/HCV-coinfected patients.
 Mauelshagen A, Horst H, Stellbrink H, Hoffmann C.
J Int AIDS Soc. 2012 Nov 11;15(6):18416.
Abstract

Association between Exposure to Nevirapine and Reduced Liver Fibrosis Progression in Patients with HIV and Hepatitis C Virus Coinfection.
 Berenguer J, Bellón JM, Miralles P, et al  
Clin Infect Dis. 2008 Jan 1;46(1):137-43.
 Abstract
 
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E, Gutiérrez S, Jahnke N, et al
 AIDS. 2007 Jul 31;21(12):1561-156
 Abstract
 
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
 Macias J, Castellano V, Merchante N, et al.   
AIDS. 2004 Apr 12;18(5):767-774.
 Abstract
Raltegravir
 
   Journal Papers, Abstracts, and Commentaries
 
 

Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Calza L, Danese I, Colangeli V, et al
Infect Dis (Lond). 2015 Apr 15:1-12.
 Abstract

Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.
Taramasso L, Madeddu G, Ricci E,  et al.
Biomed Pharmacother. 2015 Feb;69:233-6.
 Abstract

A Switch to Raltegravir Improves Antiretroviral Associated Hepatotoxicity in Individuals Coinfected with HIV and Hepatitis C.
Cevik M, Katsarolis I, J Singh G, Nelson M
J Infect. 2014 May 1.
Abstract

Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
 Hernández-Novoa B, Moreno A, Pérez-Elías MJ,  et al 
J Antimicrob Chemother. 2013 Oct 4
 Abstract

Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals.
 Cevik M, Jagjit Singh G, Dickinson L, Nelson M.
J Int AIDS Soc. 2012 Nov 11;15(6):18419
 Abstract

Safety and efficacy of raltegravir in patients co-infected with HIV and hepatitis B and/or C virus: complete data from Phase III double-blind studies.
 Rockstroh J, Sklar P, Wan H,  
J Int AIDS Soc. 2012 Nov 11;15(6):18415.
Abstract

Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals.
Cevik M, Jagjit Singh G, Dickinson L, Nelson M.
J Int AIDS Soc. 2012 Nov 11;15(6):1841
 Abstract

Safe Coadministration of Raltegravir-Based HAART in HIV-Infected Patients With HCV-Cirrhosis Receiving Triple Therapy With Telaprevir or Boceprevir.
Moreno A, Quereda C, Montes M,  et al
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):e47-9
 Abstract

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.
Weimer LE, Fragola V, Floridia M,  et al
J Antimicrob Chemother. 2012 Sep 14.
Abstract
Raltegravir
 
   Journal Papers, Abstracts, and Commentaries
 
  Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
Hernández-Novoa B, Moreno A, Pérez-Elías MJ, et al
J Antimicrob Chemother. 2014 Feb;69(2):471-5.
 Abstract
Ritonavir
 
   Journal Papers, Abstracts, and Commentaries
 
  Lower ribavirin plasma concentrations in HCV/HIV co-infected patients than in HCV mono-infected patients despite similar dosage.
 Deenen MJ, de Kanter CT, Dofferhoff AS,  et al
Ther Drug Monit. 2015 Jun 19.
 Abstract

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
 Neukam K, Mira JA, Ruiz-Morales J, et al
J Antimicrob Chemother. 2011 Sep 7.
Abstract
Tenofovir
 
   Journal Papers, Abstracts, and Commentaries
 
  Role of tenofovir in HIV and hepatitis C virus coinfection.
Tuma P, Vispo E, Barreiro P, Soriano V.
Enferm Infecc Microbiol Clin. 2008 Jun;26(Supl.8):31-37
 Abstract
Tipranavir
 

     Journal Papers, Abstracts, and Commentaries

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.
Macías J, Orihuela F, Rivero A, et al
 J Antimicrob Chemother. 2008 Oct 24.
Abstract
Zidovudine
 

     Journal Papers, Abstracts, and Commentaries

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Alvarez D, Dieterich DT, Brau N, et al
 J Viral Hepat. 2006 Oct;13(10):683-9
 Abstract

HIV/HCV Main Page Main New/Newsworthy  Home Page

 Antiretroviral Drugs